Biological insights into BRAFv600 mutations in melanoma patient not mere therapeutic targets

Giuseppina Improta, Giuseppe Pelosi, Elena Tamborini, Marco Donia, Mario Santinami, Filippo De Braud, Filippo Fraggetta

Research output: Contribution to journalArticlepeer-review

Abstract

Some experimental evidence indicates that uncommon BRAF mutations consisting in the substitution of 2 adjacent nucleotides within codon 600 are in a cis configuration and associate with BRAF gene amplification. These findings suggest that BRAFV600 mutations are unlikely to occur as homozygous alterations in clinical melanoma samples, with gene amplification perhaps contributing to mask the heterozygous state.

Original languageEnglish
Article numbere25594
JournalOncoImmunology
Volume2
Issue number8
DOIs
Publication statusPublished - 2013

Keywords

  • BRAF
  • Homozygosis
  • Immunotherapy
  • Melanoma
  • MHC
  • Vemurafenib

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Fingerprint

Dive into the research topics of 'Biological insights into BRAFv600 mutations in melanoma patient not mere therapeutic targets'. Together they form a unique fingerprint.

Cite this